Global Insomnia Therapeutics Market
Global Insomnia Therapeutics Market

Insomnia Therapeutics Comprehensive Study by Type (Pharmacological Treatments (Prescription Sleep Aids, Over-the-Counter Sleep Aids), Non-pharmacological Treatments), Application (Clinics, Hospitals), Insomnia Type (Transient Insomnia, Acute Insomnia, Chronic Insomnia) Players and Region - Global Market Outlook to 2026

Insomnia Therapeutics Market Segmented into XX Submarkets. | Forecast Years: 2021- 2026  

Feb 2021 Edition 220 Pages 216 Tables & Figures
  • Summary
  • Market Segments
  • Table of Content
  • List of Tables & Figures
  • Companies Mentioned
What is Insomnia Therapeutics Market?

Insomnia is a sleep disorder in which the person has difficulty sleeping or sleeping. Symptoms are low stamina, daytime sleepiness, depression, and irritability. It is a common disease affecting millions of people around the world. Insomnia-related disorders are caused by disorders of the circadian rhythm, chronic pain, hyperthyroidism, menopause, psychological stress, and other disorders. In addition, excessive consumption of drugs like caffeine, alcohol, and nicotine can lead to insomnia. This disorder can be diagnosed in sleep laboratories with a variety of diagnostic equipment. Depending upon the duration of the disorder, insomnia is thereby divided into three types, namely transient, acute and chronic insomnia. In transient insomnia, symptoms persist for a few days to a few weeks; acute insomnia lasts for several weeks and chronic insomnia lasts for months to several years.

The market study is being classified by Type (Pharmacological Treatments [Prescription Sleep Aids, Over-the-Counter Sleep Aids] and Non-pharmacological Treatments), by Application (Clinics and Hospitals) and major geographies with country level break-up.

Eisai, Co. Ltd. (Japan), Merck & Co., Inc. (United States), Mylan N.V. (United States), Meda Consumer Healthcare Inc. (United States), Eli Lilly and Company (United States), Pfizer, Inc. (United States), Sanofi (France), Takeda Pharmaceutical Company Ltd. (Japan), Pernix Therapeutics (United States), Sumitomo Dainippon Pharma Co., Ltd. (Japan), ECR Pharmaceuticals (United States), Purdue Pharma L.P. (United States) and Vanda Pharmaceuticals, Inc. (United States) are some of the key players profiled in the study. Additionally, the Players which are also part of the research are Ebb Therapeutics (United States), Fidia Farmaceutici (Italy) and Paratek Pharmaceuticals Inc. (United States).

The companies are now exploring the market by adopting mergers & acquisitions, expansions, investments, new developments in existing products, and collaborations as their preferred strategies. The players are also exploring new geographies and industries through expansions and acquisitions so as to avail a competitive advantage through combined synergies. Research Analyst at AMA predicts that United States Players will contribute to the maximum growth of Global Insomnia Therapeutics market throughout the predicted period.

Segment Analysis
Analyst at AMA have segmented the market study of Global Insomnia Therapeutics market by Type, Application and Region.

On the basis of geography, the market of Insomnia Therapeutics has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Market Drivers
  • Increasing Prevalence of Insomnia across the World
  • Rising Stress Level
  • A Rise in Shift-Work Sleep Disorder and Increased Stress Level
  • Growing Geriatric Population
  • Increasing Awareness about Various Treatment Options
  • Growing Awareness about the Advantages of Melatonin and Valerian Roots

Market Trend
  • The Emergence of Newer Therapeutics with Lesser Adverse Effects
  • The Rise in Constantly Improving Healthcare Reimbursement Policies
  • A Paradigm Shift Due To Rising Awareness among Patients

Restraints
  • Prolonged Use of These Drugs May Lead To Resistance

Opportunities
  • Growing Demand for Sleep Disorder Treatment in the Emerging Economies
  • High Healthcare Spending
  • Development of New Technologies and Introduction of Medical Devices

Challenges
  • Higher Adoption of Generic Products That Are Available In Cheaper Price





Key Target Audience
Providers of Insomnia Therapeutics, Potential Investors, Market Research Firms, Regulatory Bodies, End-Users and Others

Customization in the Report Available:
The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be informed prior purchase
Report Objectives / Segmentation Covered
By Type
  • Pharmacological Treatments [Prescription Sleep Aids, Over-the-Counter Sleep Aids]
  • Non-pharmacological Treatments
By Application
  • Clinics
  • Hospitals
By Insomnia Type
  • Transient Insomnia
  • Acute Insomnia
  • Chronic Insomnia

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increasing Prevalence of Insomnia across the World
      • 3.2.2. Rising Stress Level
      • 3.2.3. A Rise in Shift-Work Sleep Disorder and Increased Stress Level
      • 3.2.4. Growing Geriatric Population
      • 3.2.5. Increasing Awareness about Various Treatment Options
      • 3.2.6. Growing Awareness about the Advantages of Melatonin and Valerian Roots
    • 3.3. Market Challenges
      • 3.3.1. Higher Adoption of Generic Products That Are Available In Cheaper Price
    • 3.4. Market Trends
      • 3.4.1. The Emergence of Newer Therapeutics with Lesser Adverse Effects
      • 3.4.2. The Rise in Constantly Improving Healthcare Reimbursement Policies
      • 3.4.3. A Paradigm Shift Due To Rising Awareness among Patients
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Insomnia Therapeutics, by Type, Application, Insomnia Type and Region (value and price ) (2015-2020)
    • 5.1. Introduction
    • 5.2. Global Insomnia Therapeutics (Value)
      • 5.2.1. Global Insomnia Therapeutics by: Type (Value)
        • 5.2.1.1. Pharmacological Treatments [Prescription Sleep Aids, Over-the-Counter Sleep Aids]
        • 5.2.1.2. Non-pharmacological Treatments
      • 5.2.2. Global Insomnia Therapeutics by: Application (Value)
        • 5.2.2.1. Clinics
        • 5.2.2.2. Hospitals
      • 5.2.3. Global Insomnia Therapeutics by: Insomnia Type (Value)
        • 5.2.3.1. Transient Insomnia
        • 5.2.3.2. Acute Insomnia
        • 5.2.3.3. Chronic Insomnia
      • 5.2.4. Global Insomnia Therapeutics Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
    • 5.3. Global Insomnia Therapeutics (Price)
      • 5.3.1. Global Insomnia Therapeutics by: Type (Price)
  • 6. Insomnia Therapeutics: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2020)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Eisai, Co. Ltd. (Japan)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Merck & Co., Inc. (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Mylan N.V. (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Meda Consumer Healthcare Inc. (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Eli Lilly and Company (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Pfizer, Inc. (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Sanofi (France)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Takeda Pharmaceutical Company Ltd. (Japan)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Pernix Therapeutics (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Sumitomo Dainippon Pharma Co., Ltd. (Japan)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
      • 6.4.11. ECR Pharmaceuticals (United States)
        • 6.4.11.1. Business Overview
        • 6.4.11.2. Products/Services Offerings
        • 6.4.11.3. Financial Analysis
        • 6.4.11.4. SWOT Analysis
      • 6.4.12. Purdue Pharma L.P. (United States)
        • 6.4.12.1. Business Overview
        • 6.4.12.2. Products/Services Offerings
        • 6.4.12.3. Financial Analysis
        • 6.4.12.4. SWOT Analysis
      • 6.4.13. Vanda Pharmaceuticals, Inc. (United States)
        • 6.4.13.1. Business Overview
        • 6.4.13.2. Products/Services Offerings
        • 6.4.13.3. Financial Analysis
        • 6.4.13.4. SWOT Analysis
  • 7. Global Insomnia Therapeutics Sale, by Type, Application, Insomnia Type and Region (value and price ) (2021-2026)
    • 7.1. Introduction
    • 7.2. Global Insomnia Therapeutics (Value)
      • 7.2.1. Global Insomnia Therapeutics by: Type (Value)
        • 7.2.1.1. Pharmacological Treatments [Prescription Sleep Aids, Over-the-Counter Sleep Aids]
        • 7.2.1.2. Non-pharmacological Treatments
      • 7.2.2. Global Insomnia Therapeutics by: Application (Value)
        • 7.2.2.1. Clinics
        • 7.2.2.2. Hospitals
      • 7.2.3. Global Insomnia Therapeutics by: Insomnia Type (Value)
        • 7.2.3.1. Transient Insomnia
        • 7.2.3.2. Acute Insomnia
        • 7.2.3.3. Chronic Insomnia
      • 7.2.4. Global Insomnia Therapeutics Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
    • 7.3. Global Insomnia Therapeutics (Price)
      • 7.3.1. Global Insomnia Therapeutics by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Insomnia Therapeutics: by Type(USD Million)
  • Table 2. Insomnia Therapeutics Pharmacological Treatments [Prescription Sleep Aids, Over-the-Counter Sleep Aids] , by Region USD Million (2015-2020)
  • Table 3. Insomnia Therapeutics Non-pharmacological Treatments , by Region USD Million (2015-2020)
  • Table 4. Insomnia Therapeutics: by Application(USD Million)
  • Table 5. Insomnia Therapeutics Clinics , by Region USD Million (2015-2020)
  • Table 6. Insomnia Therapeutics Hospitals , by Region USD Million (2015-2020)
  • Table 7. Insomnia Therapeutics: by Insomnia Type(USD Million)
  • Table 8. Insomnia Therapeutics Transient Insomnia , by Region USD Million (2015-2020)
  • Table 9. Insomnia Therapeutics Acute Insomnia , by Region USD Million (2015-2020)
  • Table 10. Insomnia Therapeutics Chronic Insomnia , by Region USD Million (2015-2020)
  • Table 11. South America Insomnia Therapeutics, by Country USD Million (2015-2020)
  • Table 12. South America Insomnia Therapeutics, by Type USD Million (2015-2020)
  • Table 13. South America Insomnia Therapeutics, by Application USD Million (2015-2020)
  • Table 14. South America Insomnia Therapeutics, by Insomnia Type USD Million (2015-2020)
  • Table 15. Brazil Insomnia Therapeutics, by Type USD Million (2015-2020)
  • Table 16. Brazil Insomnia Therapeutics, by Application USD Million (2015-2020)
  • Table 17. Brazil Insomnia Therapeutics, by Insomnia Type USD Million (2015-2020)
  • Table 18. Argentina Insomnia Therapeutics, by Type USD Million (2015-2020)
  • Table 19. Argentina Insomnia Therapeutics, by Application USD Million (2015-2020)
  • Table 20. Argentina Insomnia Therapeutics, by Insomnia Type USD Million (2015-2020)
  • Table 21. Rest of South America Insomnia Therapeutics, by Type USD Million (2015-2020)
  • Table 22. Rest of South America Insomnia Therapeutics, by Application USD Million (2015-2020)
  • Table 23. Rest of South America Insomnia Therapeutics, by Insomnia Type USD Million (2015-2020)
  • Table 24. Asia Pacific Insomnia Therapeutics, by Country USD Million (2015-2020)
  • Table 25. Asia Pacific Insomnia Therapeutics, by Type USD Million (2015-2020)
  • Table 26. Asia Pacific Insomnia Therapeutics, by Application USD Million (2015-2020)
  • Table 27. Asia Pacific Insomnia Therapeutics, by Insomnia Type USD Million (2015-2020)
  • Table 28. China Insomnia Therapeutics, by Type USD Million (2015-2020)
  • Table 29. China Insomnia Therapeutics, by Application USD Million (2015-2020)
  • Table 30. China Insomnia Therapeutics, by Insomnia Type USD Million (2015-2020)
  • Table 31. Japan Insomnia Therapeutics, by Type USD Million (2015-2020)
  • Table 32. Japan Insomnia Therapeutics, by Application USD Million (2015-2020)
  • Table 33. Japan Insomnia Therapeutics, by Insomnia Type USD Million (2015-2020)
  • Table 34. India Insomnia Therapeutics, by Type USD Million (2015-2020)
  • Table 35. India Insomnia Therapeutics, by Application USD Million (2015-2020)
  • Table 36. India Insomnia Therapeutics, by Insomnia Type USD Million (2015-2020)
  • Table 37. South Korea Insomnia Therapeutics, by Type USD Million (2015-2020)
  • Table 38. South Korea Insomnia Therapeutics, by Application USD Million (2015-2020)
  • Table 39. South Korea Insomnia Therapeutics, by Insomnia Type USD Million (2015-2020)
  • Table 40. Taiwan Insomnia Therapeutics, by Type USD Million (2015-2020)
  • Table 41. Taiwan Insomnia Therapeutics, by Application USD Million (2015-2020)
  • Table 42. Taiwan Insomnia Therapeutics, by Insomnia Type USD Million (2015-2020)
  • Table 43. Australia Insomnia Therapeutics, by Type USD Million (2015-2020)
  • Table 44. Australia Insomnia Therapeutics, by Application USD Million (2015-2020)
  • Table 45. Australia Insomnia Therapeutics, by Insomnia Type USD Million (2015-2020)
  • Table 46. Rest of Asia-Pacific Insomnia Therapeutics, by Type USD Million (2015-2020)
  • Table 47. Rest of Asia-Pacific Insomnia Therapeutics, by Application USD Million (2015-2020)
  • Table 48. Rest of Asia-Pacific Insomnia Therapeutics, by Insomnia Type USD Million (2015-2020)
  • Table 49. Europe Insomnia Therapeutics, by Country USD Million (2015-2020)
  • Table 50. Europe Insomnia Therapeutics, by Type USD Million (2015-2020)
  • Table 51. Europe Insomnia Therapeutics, by Application USD Million (2015-2020)
  • Table 52. Europe Insomnia Therapeutics, by Insomnia Type USD Million (2015-2020)
  • Table 53. Germany Insomnia Therapeutics, by Type USD Million (2015-2020)
  • Table 54. Germany Insomnia Therapeutics, by Application USD Million (2015-2020)
  • Table 55. Germany Insomnia Therapeutics, by Insomnia Type USD Million (2015-2020)
  • Table 56. France Insomnia Therapeutics, by Type USD Million (2015-2020)
  • Table 57. France Insomnia Therapeutics, by Application USD Million (2015-2020)
  • Table 58. France Insomnia Therapeutics, by Insomnia Type USD Million (2015-2020)
  • Table 59. Italy Insomnia Therapeutics, by Type USD Million (2015-2020)
  • Table 60. Italy Insomnia Therapeutics, by Application USD Million (2015-2020)
  • Table 61. Italy Insomnia Therapeutics, by Insomnia Type USD Million (2015-2020)
  • Table 62. United Kingdom Insomnia Therapeutics, by Type USD Million (2015-2020)
  • Table 63. United Kingdom Insomnia Therapeutics, by Application USD Million (2015-2020)
  • Table 64. United Kingdom Insomnia Therapeutics, by Insomnia Type USD Million (2015-2020)
  • Table 65. Netherlands Insomnia Therapeutics, by Type USD Million (2015-2020)
  • Table 66. Netherlands Insomnia Therapeutics, by Application USD Million (2015-2020)
  • Table 67. Netherlands Insomnia Therapeutics, by Insomnia Type USD Million (2015-2020)
  • Table 68. Rest of Europe Insomnia Therapeutics, by Type USD Million (2015-2020)
  • Table 69. Rest of Europe Insomnia Therapeutics, by Application USD Million (2015-2020)
  • Table 70. Rest of Europe Insomnia Therapeutics, by Insomnia Type USD Million (2015-2020)
  • Table 71. MEA Insomnia Therapeutics, by Country USD Million (2015-2020)
  • Table 72. MEA Insomnia Therapeutics, by Type USD Million (2015-2020)
  • Table 73. MEA Insomnia Therapeutics, by Application USD Million (2015-2020)
  • Table 74. MEA Insomnia Therapeutics, by Insomnia Type USD Million (2015-2020)
  • Table 75. Middle East Insomnia Therapeutics, by Type USD Million (2015-2020)
  • Table 76. Middle East Insomnia Therapeutics, by Application USD Million (2015-2020)
  • Table 77. Middle East Insomnia Therapeutics, by Insomnia Type USD Million (2015-2020)
  • Table 78. Africa Insomnia Therapeutics, by Type USD Million (2015-2020)
  • Table 79. Africa Insomnia Therapeutics, by Application USD Million (2015-2020)
  • Table 80. Africa Insomnia Therapeutics, by Insomnia Type USD Million (2015-2020)
  • Table 81. North America Insomnia Therapeutics, by Country USD Million (2015-2020)
  • Table 82. North America Insomnia Therapeutics, by Type USD Million (2015-2020)
  • Table 83. North America Insomnia Therapeutics, by Application USD Million (2015-2020)
  • Table 84. North America Insomnia Therapeutics, by Insomnia Type USD Million (2015-2020)
  • Table 85. United States Insomnia Therapeutics, by Type USD Million (2015-2020)
  • Table 86. United States Insomnia Therapeutics, by Application USD Million (2015-2020)
  • Table 87. United States Insomnia Therapeutics, by Insomnia Type USD Million (2015-2020)
  • Table 88. Canada Insomnia Therapeutics, by Type USD Million (2015-2020)
  • Table 89. Canada Insomnia Therapeutics, by Application USD Million (2015-2020)
  • Table 90. Canada Insomnia Therapeutics, by Insomnia Type USD Million (2015-2020)
  • Table 91. Mexico Insomnia Therapeutics, by Type USD Million (2015-2020)
  • Table 92. Mexico Insomnia Therapeutics, by Application USD Million (2015-2020)
  • Table 93. Mexico Insomnia Therapeutics, by Insomnia Type USD Million (2015-2020)
  • Table 94. Insomnia Therapeutics: by Type(USD/Units)
  • Table 95. Company Basic Information, Sales Area and Its Competitors
  • Table 96. Company Basic Information, Sales Area and Its Competitors
  • Table 97. Company Basic Information, Sales Area and Its Competitors
  • Table 98. Company Basic Information, Sales Area and Its Competitors
  • Table 99. Company Basic Information, Sales Area and Its Competitors
  • Table 100. Company Basic Information, Sales Area and Its Competitors
  • Table 101. Company Basic Information, Sales Area and Its Competitors
  • Table 102. Company Basic Information, Sales Area and Its Competitors
  • Table 103. Company Basic Information, Sales Area and Its Competitors
  • Table 104. Company Basic Information, Sales Area and Its Competitors
  • Table 105. Company Basic Information, Sales Area and Its Competitors
  • Table 106. Company Basic Information, Sales Area and Its Competitors
  • Table 107. Company Basic Information, Sales Area and Its Competitors
  • Table 108. Insomnia Therapeutics: by Type(USD Million)
  • Table 109. Insomnia Therapeutics Pharmacological Treatments [Prescription Sleep Aids, Over-the-Counter Sleep Aids] , by Region USD Million (2021-2026)
  • Table 110. Insomnia Therapeutics Non-pharmacological Treatments , by Region USD Million (2021-2026)
  • Table 111. Insomnia Therapeutics: by Application(USD Million)
  • Table 112. Insomnia Therapeutics Clinics , by Region USD Million (2021-2026)
  • Table 113. Insomnia Therapeutics Hospitals , by Region USD Million (2021-2026)
  • Table 114. Insomnia Therapeutics: by Insomnia Type(USD Million)
  • Table 115. Insomnia Therapeutics Transient Insomnia , by Region USD Million (2021-2026)
  • Table 116. Insomnia Therapeutics Acute Insomnia , by Region USD Million (2021-2026)
  • Table 117. Insomnia Therapeutics Chronic Insomnia , by Region USD Million (2021-2026)
  • Table 118. South America Insomnia Therapeutics, by Country USD Million (2021-2026)
  • Table 119. South America Insomnia Therapeutics, by Type USD Million (2021-2026)
  • Table 120. South America Insomnia Therapeutics, by Application USD Million (2021-2026)
  • Table 121. South America Insomnia Therapeutics, by Insomnia Type USD Million (2021-2026)
  • Table 122. Brazil Insomnia Therapeutics, by Type USD Million (2021-2026)
  • Table 123. Brazil Insomnia Therapeutics, by Application USD Million (2021-2026)
  • Table 124. Brazil Insomnia Therapeutics, by Insomnia Type USD Million (2021-2026)
  • Table 125. Argentina Insomnia Therapeutics, by Type USD Million (2021-2026)
  • Table 126. Argentina Insomnia Therapeutics, by Application USD Million (2021-2026)
  • Table 127. Argentina Insomnia Therapeutics, by Insomnia Type USD Million (2021-2026)
  • Table 128. Rest of South America Insomnia Therapeutics, by Type USD Million (2021-2026)
  • Table 129. Rest of South America Insomnia Therapeutics, by Application USD Million (2021-2026)
  • Table 130. Rest of South America Insomnia Therapeutics, by Insomnia Type USD Million (2021-2026)
  • Table 131. Asia Pacific Insomnia Therapeutics, by Country USD Million (2021-2026)
  • Table 132. Asia Pacific Insomnia Therapeutics, by Type USD Million (2021-2026)
  • Table 133. Asia Pacific Insomnia Therapeutics, by Application USD Million (2021-2026)
  • Table 134. Asia Pacific Insomnia Therapeutics, by Insomnia Type USD Million (2021-2026)
  • Table 135. China Insomnia Therapeutics, by Type USD Million (2021-2026)
  • Table 136. China Insomnia Therapeutics, by Application USD Million (2021-2026)
  • Table 137. China Insomnia Therapeutics, by Insomnia Type USD Million (2021-2026)
  • Table 138. Japan Insomnia Therapeutics, by Type USD Million (2021-2026)
  • Table 139. Japan Insomnia Therapeutics, by Application USD Million (2021-2026)
  • Table 140. Japan Insomnia Therapeutics, by Insomnia Type USD Million (2021-2026)
  • Table 141. India Insomnia Therapeutics, by Type USD Million (2021-2026)
  • Table 142. India Insomnia Therapeutics, by Application USD Million (2021-2026)
  • Table 143. India Insomnia Therapeutics, by Insomnia Type USD Million (2021-2026)
  • Table 144. South Korea Insomnia Therapeutics, by Type USD Million (2021-2026)
  • Table 145. South Korea Insomnia Therapeutics, by Application USD Million (2021-2026)
  • Table 146. South Korea Insomnia Therapeutics, by Insomnia Type USD Million (2021-2026)
  • Table 147. Taiwan Insomnia Therapeutics, by Type USD Million (2021-2026)
  • Table 148. Taiwan Insomnia Therapeutics, by Application USD Million (2021-2026)
  • Table 149. Taiwan Insomnia Therapeutics, by Insomnia Type USD Million (2021-2026)
  • Table 150. Australia Insomnia Therapeutics, by Type USD Million (2021-2026)
  • Table 151. Australia Insomnia Therapeutics, by Application USD Million (2021-2026)
  • Table 152. Australia Insomnia Therapeutics, by Insomnia Type USD Million (2021-2026)
  • Table 153. Rest of Asia-Pacific Insomnia Therapeutics, by Type USD Million (2021-2026)
  • Table 154. Rest of Asia-Pacific Insomnia Therapeutics, by Application USD Million (2021-2026)
  • Table 155. Rest of Asia-Pacific Insomnia Therapeutics, by Insomnia Type USD Million (2021-2026)
  • Table 156. Europe Insomnia Therapeutics, by Country USD Million (2021-2026)
  • Table 157. Europe Insomnia Therapeutics, by Type USD Million (2021-2026)
  • Table 158. Europe Insomnia Therapeutics, by Application USD Million (2021-2026)
  • Table 159. Europe Insomnia Therapeutics, by Insomnia Type USD Million (2021-2026)
  • Table 160. Germany Insomnia Therapeutics, by Type USD Million (2021-2026)
  • Table 161. Germany Insomnia Therapeutics, by Application USD Million (2021-2026)
  • Table 162. Germany Insomnia Therapeutics, by Insomnia Type USD Million (2021-2026)
  • Table 163. France Insomnia Therapeutics, by Type USD Million (2021-2026)
  • Table 164. France Insomnia Therapeutics, by Application USD Million (2021-2026)
  • Table 165. France Insomnia Therapeutics, by Insomnia Type USD Million (2021-2026)
  • Table 166. Italy Insomnia Therapeutics, by Type USD Million (2021-2026)
  • Table 167. Italy Insomnia Therapeutics, by Application USD Million (2021-2026)
  • Table 168. Italy Insomnia Therapeutics, by Insomnia Type USD Million (2021-2026)
  • Table 169. United Kingdom Insomnia Therapeutics, by Type USD Million (2021-2026)
  • Table 170. United Kingdom Insomnia Therapeutics, by Application USD Million (2021-2026)
  • Table 171. United Kingdom Insomnia Therapeutics, by Insomnia Type USD Million (2021-2026)
  • Table 172. Netherlands Insomnia Therapeutics, by Type USD Million (2021-2026)
  • Table 173. Netherlands Insomnia Therapeutics, by Application USD Million (2021-2026)
  • Table 174. Netherlands Insomnia Therapeutics, by Insomnia Type USD Million (2021-2026)
  • Table 175. Rest of Europe Insomnia Therapeutics, by Type USD Million (2021-2026)
  • Table 176. Rest of Europe Insomnia Therapeutics, by Application USD Million (2021-2026)
  • Table 177. Rest of Europe Insomnia Therapeutics, by Insomnia Type USD Million (2021-2026)
  • Table 178. MEA Insomnia Therapeutics, by Country USD Million (2021-2026)
  • Table 179. MEA Insomnia Therapeutics, by Type USD Million (2021-2026)
  • Table 180. MEA Insomnia Therapeutics, by Application USD Million (2021-2026)
  • Table 181. MEA Insomnia Therapeutics, by Insomnia Type USD Million (2021-2026)
  • Table 182. Middle East Insomnia Therapeutics, by Type USD Million (2021-2026)
  • Table 183. Middle East Insomnia Therapeutics, by Application USD Million (2021-2026)
  • Table 184. Middle East Insomnia Therapeutics, by Insomnia Type USD Million (2021-2026)
  • Table 185. Africa Insomnia Therapeutics, by Type USD Million (2021-2026)
  • Table 186. Africa Insomnia Therapeutics, by Application USD Million (2021-2026)
  • Table 187. Africa Insomnia Therapeutics, by Insomnia Type USD Million (2021-2026)
  • Table 188. North America Insomnia Therapeutics, by Country USD Million (2021-2026)
  • Table 189. North America Insomnia Therapeutics, by Type USD Million (2021-2026)
  • Table 190. North America Insomnia Therapeutics, by Application USD Million (2021-2026)
  • Table 191. North America Insomnia Therapeutics, by Insomnia Type USD Million (2021-2026)
  • Table 192. United States Insomnia Therapeutics, by Type USD Million (2021-2026)
  • Table 193. United States Insomnia Therapeutics, by Application USD Million (2021-2026)
  • Table 194. United States Insomnia Therapeutics, by Insomnia Type USD Million (2021-2026)
  • Table 195. Canada Insomnia Therapeutics, by Type USD Million (2021-2026)
  • Table 196. Canada Insomnia Therapeutics, by Application USD Million (2021-2026)
  • Table 197. Canada Insomnia Therapeutics, by Insomnia Type USD Million (2021-2026)
  • Table 198. Mexico Insomnia Therapeutics, by Type USD Million (2021-2026)
  • Table 199. Mexico Insomnia Therapeutics, by Application USD Million (2021-2026)
  • Table 200. Mexico Insomnia Therapeutics, by Insomnia Type USD Million (2021-2026)
  • Table 201. Insomnia Therapeutics: by Type(USD/Units)
  • Table 202. Research Programs/Design for This Report
  • Table 203. Key Data Information from Secondary Sources
  • Table 204. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Insomnia Therapeutics: by Type USD Million (2015-2020)
  • Figure 5. Global Insomnia Therapeutics: by Application USD Million (2015-2020)
  • Figure 6. Global Insomnia Therapeutics: by Insomnia Type USD Million (2015-2020)
  • Figure 7. South America Insomnia Therapeutics Share (%), by Country
  • Figure 8. Asia Pacific Insomnia Therapeutics Share (%), by Country
  • Figure 9. Europe Insomnia Therapeutics Share (%), by Country
  • Figure 10. MEA Insomnia Therapeutics Share (%), by Country
  • Figure 11. North America Insomnia Therapeutics Share (%), by Country
  • Figure 12. Global Insomnia Therapeutics: by Type USD/Units (2015-2020)
  • Figure 13. Global Insomnia Therapeutics share by Players 2020 (%)
  • Figure 14. Global Insomnia Therapeutics share by Players (Top 3) 2020(%)
  • Figure 15. Global Insomnia Therapeutics share by Players (Top 5) 2020(%)
  • Figure 16. BCG Matrix for key Companies
  • Figure 17. Eisai, Co. Ltd. (Japan) Revenue, Net Income and Gross profit
  • Figure 18. Eisai, Co. Ltd. (Japan) Revenue: by Geography 2020
  • Figure 19. Merck & Co., Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 20. Merck & Co., Inc. (United States) Revenue: by Geography 2020
  • Figure 21. Mylan N.V. (United States) Revenue, Net Income and Gross profit
  • Figure 22. Mylan N.V. (United States) Revenue: by Geography 2020
  • Figure 23. Meda Consumer Healthcare Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 24. Meda Consumer Healthcare Inc. (United States) Revenue: by Geography 2020
  • Figure 25. Eli Lilly and Company (United States) Revenue, Net Income and Gross profit
  • Figure 26. Eli Lilly and Company (United States) Revenue: by Geography 2020
  • Figure 27. Pfizer, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 28. Pfizer, Inc. (United States) Revenue: by Geography 2020
  • Figure 29. Sanofi (France) Revenue, Net Income and Gross profit
  • Figure 30. Sanofi (France) Revenue: by Geography 2020
  • Figure 31. Takeda Pharmaceutical Company Ltd. (Japan) Revenue, Net Income and Gross profit
  • Figure 32. Takeda Pharmaceutical Company Ltd. (Japan) Revenue: by Geography 2020
  • Figure 33. Pernix Therapeutics (United States) Revenue, Net Income and Gross profit
  • Figure 34. Pernix Therapeutics (United States) Revenue: by Geography 2020
  • Figure 35. Sumitomo Dainippon Pharma Co., Ltd. (Japan) Revenue, Net Income and Gross profit
  • Figure 36. Sumitomo Dainippon Pharma Co., Ltd. (Japan) Revenue: by Geography 2020
  • Figure 37. ECR Pharmaceuticals (United States) Revenue, Net Income and Gross profit
  • Figure 38. ECR Pharmaceuticals (United States) Revenue: by Geography 2020
  • Figure 39. Purdue Pharma L.P. (United States) Revenue, Net Income and Gross profit
  • Figure 40. Purdue Pharma L.P. (United States) Revenue: by Geography 2020
  • Figure 41. Vanda Pharmaceuticals, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 42. Vanda Pharmaceuticals, Inc. (United States) Revenue: by Geography 2020
  • Figure 43. Global Insomnia Therapeutics: by Type USD Million (2021-2026)
  • Figure 44. Global Insomnia Therapeutics: by Application USD Million (2021-2026)
  • Figure 45. Global Insomnia Therapeutics: by Insomnia Type USD Million (2021-2026)
  • Figure 46. South America Insomnia Therapeutics Share (%), by Country
  • Figure 47. Asia Pacific Insomnia Therapeutics Share (%), by Country
  • Figure 48. Europe Insomnia Therapeutics Share (%), by Country
  • Figure 49. MEA Insomnia Therapeutics Share (%), by Country
  • Figure 50. North America Insomnia Therapeutics Share (%), by Country
  • Figure 51. Global Insomnia Therapeutics: by Type USD/Units (2021-2026)
Some of the key companies/manufacturers profiled in the report
  • Eisai, Co. Ltd. (Japan)
  • Merck & Co., Inc. (United States)
  • Mylan N.V. (United States)
  • Meda Consumer Healthcare Inc. (United States)
  • Eli Lilly and Company (United States)
  • Pfizer, Inc. (United States)
  • Sanofi (France)
  • Takeda Pharmaceutical Company Ltd. (Japan)
  • Pernix Therapeutics (United States)
  • Sumitomo Dainippon Pharma Co., Ltd. (Japan)
  • ECR Pharmaceuticals (United States)
  • Purdue Pharma L.P. (United States)
  • Vanda Pharmaceuticals, Inc. (United States)
Additional players considered in the study are as follows:
Ebb Therapeutics (United States) , Fidia Farmaceutici (Italy) , Paratek Pharmaceuticals Inc. (United States)
Select License Type
Sample Report Enquiry Before Buy Request Discount

Speak with Analyst

Want to find out more about this report?

Get Free Consultation